Neurocrine Biosciences announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (Valbenazine) capsules when used for the long-term treatment of adults with chorea associated with Huntington's disease (HD). Interim data suggest one-capsule, once-daily INGREZZA improved chorea at the first evaluation at Week 2 with sustained efficacy through Week 50. INGREZZA® (Valbenazine) is the only one-capsule, once-daily selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by FDA for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.